Convergent Therapeutics, Inc.

We are excited to share our new company brand, reflecting our mission to unlock the full potential of alpha radioantibodies to benefit the lives of patients who are battling cancer. Learn more about Convergent, CONV01-α and our science: https://convergentrx.com/

Today, we announced that data for our lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to actinium-225, will be presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 13-15, 2025, in San Francisco, California. Presentations include clinical follow up of a Phase I dose-escalation trial exploring the addition of CONV01-α to 177Lu-PSMA-I&T, a PSMA-targeted beta emitting small molecule for the treatment of advanced prostate cancer, and a trial in progress presentation of the three-part Phase II CONVERGE-01 study. To read the full press release, visit: https://lnkd.in/d7rYUe4N

Don’t miss us at the 24th PMWC - Precision Medicine World Conference (PMWC 2025) from February 5-7, 2025, at the Santa Clara Convention Center, CA—a premier forum for leaders transforming the future of healthcare, co-hosted by Stanford and UCSF. Jones Nauseef, MD PhD, Senior Medical Director at Convergent Therapeutics will be a panelist during the Oncology Applications track on Wednesday, February 5th at 9.45 A.M.-10.30 A.M. This session, as led by Dr. William Oh, is entitled “Radiopharmaceuticals for Cancer.” We look forward to seeing everyone there. #PMWC25

We are excited to head to San Francisco for the 43rd Annual J.P. Morgan Healthcare Conference to share more about CONV01-α and our pipeline of novel α-radioantibodies. We look forward to hearing insights and trends shaping the industry. #JPM2025

Yesterday, we announced the appointment of Barbara Duncan to our Board of Directors. "Barbara is a welcome addition to our Board of Directors, bringing deep experience in biopharmaceutical leadership," said Convergent's Co-founder and CEO, Philip Kantoff, MD. "We are confident that she will be an important asset to the Board as we continue to drive our pipeline through clinical development." To read the full announcement, visit: https://lnkd.in/eWDNEkiy

This morning, we announced the receipt of the first shipments of non-carrier added (n.c.a.) Actinium 225 (Ac-225) from Cardinal Health to support the CONVERGE-01 Phase 2 clinical trial. Ac-225 is a high-energy, alpha-emitting radioisotope of great interest for the treatment of cancer, as it is thought to carry sufficient radiation to cause cancer cell death when bound to a targeting antibody. "This shipment will support Convergent's lead asset, CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225. CONV01-α is currently being investigated as a potentially groundbreaking treatment for prostate cancer,” said Convergent's Co-founder and CEO,?Philip Kantoff, MD. To read the full announcement, visit: https://lnkd.in/egdtqTcY

This morning, we announced the first patient has been dosed with CONV01-α in the Phase II CONVERGE-01 trial evaluating CONV01-α, Ac-225 rosopatamab tetraxetan, for the treatment of patients with prostate-specific membrane antigen (PSMA) PET-positive metastatic castration resistant prostate cancer. We are also excited to welcome Richard Messmann, M.D., M.H.S., M.Sc., as Chief Medical Officer to lead development of CONV01-α. In addition, Novo Holdings invests $40 million?in Series A Extension to advance clinical development of radiopharmaceuticals, increasing the total Series A raise to $130 million. To learn more about our pipeline and corporate updates, and read the full announcement, visit: https://lnkd.in/eXZ9xcGk

NorthStar Medical Radioisotopes and Convergent Therapeutics, Inc. Expand Strategic Collaboration Around CONV01-α https://lnkd.in/eYuV4SPM

Join us in San Diego for the 2024 US Targeted Radiopharmaceuticals Summit. Dr. Jones Nauseef, MD PhD, Senior Medical Director at Convergent Therapeutics will be presenting an update on our Actinium-225 PSMA targeted radioantibody, CONV01-α. “Targeted radiotherapies are an emerging and exciting class of anti-cancer therapeutics. Our lead asset, CONV01-alpha, is an actinium-conjugated monoclonal antibody against PSMA. I’m excited to join colleagues at Hanson Wade’s 3rd Annual Targeted Radiopharmaceuticals Summit and present on past successes and the future promise of CONV01-alpha in castration resistant prostate cancer.” For more information, visit: https://lnkd.in/e5YB65Er #ProstateCancer #Oncology #PSMA

Today, we announced that the U.S. Food and Drug Administration ("FDA") has cleared the investigational new drug ("IND") application for CONV01-α, our lead candidate for the treatment of patients with advanced prostate cancer. ? “While we have already treated well over 100 advanced prostate cancer patients in the context of investigator INDs, this new IND will allow us to rapidly advance CONV01-α into Phase 3 studies and expand the scope of clinical development of CONV01-α as a monotherapy and in combination with other cancer therapies,” said Convergent’s Co-founder and CEO, Philip Kantoff, MD. ? We are on track to conduct Phase 2 clinical trials in 2024 preparing for a registrational program in 2025. ? To learn more about CONV01-α and read the full announcement, visit: https://lnkd.in/esyxbsfb ? #ProstateCancer #Oncology